OBJECTIVE： To establish a method for simultaneous determination of valsartan and hydrochlorothiazide in Valsartan hydrochlorothiazide tablets. METHODS： UPLC was adopted. The determination was performed on Phenomenex C18 column with mobile phase consisted of [0.1％ phosphoric acid solution-acetonitrile （95 ∶ 5，V/V）]-[0.1％ phosphoric acid solution-acetonitrile （5 ∶ 95，V/V）] （gradient elution） at the flow rate of 0.25 mL/min. The detection wavelength was set at 272 nm， and the column temperature was 35 ℃. The sample size was 1.5 μL. RESULTS： The linear range were 8.1-324.2 μg/mL for valsartan （r＝0.999 9） and 1.2-50.1 μg/mL for hydrochlorothiazide （r＝0.999 9）. The limits of quantitation were 0.24， 0.04 ng， and the limits of detection were 0.06， 0.01 ng. RSDs of precision， stability and reproducibility tests were less than 2.0％； recoveries were 97.69％-100.35％ for valsartan （RSD＝1.03％，n＝9） and 98.27％-100.60％ for hydrochlorothiazide （RSD＝0.83％，n＝9）. CONCLUSIONS： The method is simple， rapid and accurate， and can be used for the simultaneous determination of valsartan and hydrochlorothiazide in Valsartan hydrochlorothiazide tablets.